Mortality due to viral hepatitis in the Global Burden of Disease Study 2010: New evidence of an urgent global public health priority demanding action

Antiviral Therapy

Volumn 18, Issue 8, 2013, Pages 953-954

  Cowie, Benjamin C ^a,b,c   Carville, Kylie S ^a   MacLachlan, Jennifer H ^a,b  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; HEALTHY PEOPLE PROGRAMS; HEPATITIS, VIRAL, HUMAN; HUMANS; ORGANOPHOSPHONATES; PUBLIC HEALTH; REVERSE TRANSCRIPTASE INHIBITORS; WORLD HEALTH;

EID: 84893515195     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2654     Document Type: Review

References (14)

1. Horton R. GBD 2010: understanding disease, injury, and risk. Lancet 2012; 380:2053-2054.
2. Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. Lancet 2012; 380:2063-2066.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-2128.
4. Ortblad KF, Lozano R, Murray CJ. The burden of HIV: insights from the GBD 2010. AIDS 2013; 27:2003-2017.
5. Cowie BC, Dore GJ. The perpetual challenge of infectious diseases. N Engl J Med 2012; 367: 89; author reply 90.
6. Prevention & Control of Viral Hepatitis Infection: Framework for Global Action. Geneva: Global Hepatitis Programme, World Health Organisation, 2012.
7. Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virology 2013; 8:371-380.
8. Cavalli F. An appeal to world leaders: stop cancer now. Lancet 2013; 381:425-426.
9. Viral hepatitis. (WHA63.18). Geneva: World Health Organisation, 2010.
10. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886-893.
11. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381:468-475.
12. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58:98-107.
13. Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013; 58:427-433.
14. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53:348-356.